| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | EpCAM |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C7812H12124N2044O2408S60 |
| Molar mass | 175130.42 g·mol |
| (verify) | |
Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).
This drug was developed by EMD Pharmaceuticals.
References
- Statement On A Nonproprietary Name Adopted By The Usan Council - Tucotuzumab Celmoleukin, American Medical Association.
- Clinical trial number NCT00016237 at ClinicalTrials.gov
- "Definition of tucotuzumab celmoleukin". National Cancer Institute.
| Interleukin receptor modulators | |||||
|---|---|---|---|---|---|
| IL-1 |
| ||||
| IL-2 |
| ||||
| IL-3 | |||||
| IL-4 |
| ||||
| IL-5 |
| ||||
| IL-6 |
| ||||
| IL-7 |
| ||||
| IL-8 |
| ||||
| IL-9 |
| ||||
| IL-10 |
| ||||
| IL-11 |
| ||||
| IL-12 |
| ||||
| IL-13 |
| ||||
| IL-15 |
| ||||
| IL-17 |
| ||||
| IL-18 |
| ||||
| IL-20 |
| ||||
| IL-21 |
| ||||
| IL-22 |
| ||||
| IL-23 |
| ||||
| IL-27 |
| ||||
| IL-28 | |||||
| IL-31 |
| ||||
| IL1RL1 |
| ||||
| IL1RL2 |
| ||||
| Others |
| ||||
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |